Comparing diagnostic performance of 131I-metaiodobenzylguanidine (131I-MIBG) and 99mTc-hydrazinonicotinyl-Tyr3-Octreotide (99mTc-HYNIC-TOC) in diagnosis and localization of pheochromocytoma and neuroblastoma
نویسندگان
چکیده مقاله:
Introduction: The present study was aimed to assess the diagnostic performance of the two imaging methods of 131I-metaiodobenzylguanidine (131I-MIBG) and 99mTc-hydrazinonicotinyl-Tyr3-Octreotide (99mTc-HYNIC-TOC) in diagnosis and localization of pheochromocytoma and neuroblastoma. Methods: This study was conducted on 40 consecutive patients with positive pathological results for pheochromocytoma or neuroblastoma. The patients underwent both I-131 131I-MIBG and octreotide scintigraphies. By using the findings of cytopathology, biomarkers, imaging studies, as well as the results of a six-month follow-up, a composite reference standard (CRS) was defined as the diagnostic gold standard. Results:Overall comparison of these two agents revealed higher sensitivity for 131I-MIBG than octreotide study both in patient-based analysis (100% vs. 80.9%, respectively), and lesion-based analysis (94.4% vs. 80.56%, respectively). In pheochromocytoma 131I-MIBG and octreotide are both highly sensitive (100%), while 131I-MIBG is more specific (100% vs. 87.5%). In neuroblastoma, 131I-MIBG is more sensitive than octreotide (100% vs. 81.25%). Conclusion: Our study shows superiority of 131I-MIBG over octreotide scanning in detection of both neuroblastoma and pheochromocytoma lesions. However, a combination of these two diagnostic tools provides more complete information on the nature and the site of lesions. The first suggested study is 131I-MIBG scanning, and if it is not available, or detecting precise location of all lesions is of concern, octreotide scanning can be helpful as a complementary study. Furthermore, in case of octreotide positive lesions, follow-up can be performed with octreotide scan with less radiation burden.
منابع مشابه
99mTc-HYNIC-TOC scintigraphy is superior to 131I-MIBG imaging in the evaluation of extraadrenal pheochromocytoma.
UNLABELLED In this investigation, the efficacy of scintigraphy using (99m)Tc-labeled hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC) in the evaluation of extraadrenal pheochromocytoma was assessed and compared with (131)I-labeled metaiodobenzylguanidine (MIBG) imaging. METHODS Ninety-seven patients who were suspected of having pheochromocytoma but showed no definite adrenal abnormalities on CT...
متن کاملPatient-specific dosimetry of 99mTc-HYNIC-Tyr3-Octreotide in children
BACKGROUND Technetium-99m-hydrazinonicotinamide-Tyr3-octreotide (99mTc-HYNIC-TOC) is recognized as a promising radiopharmaceutical for diagnosing neuroendocrine tumors (NETs). However, 99mTc-HYNIC-TOC dosimetry has been investigated only for adults. As pediatric radionuclide therapies become increasingly common, similar dosimetric studies for children are urgently needed. The aim of this study ...
متن کامل131I-MIBG in the diagnosis of primary and metastatic neuroblastoma.
OBJECTIVE Neuroblastoma is the third most common malignancy of childhood. 131I-MIBG scintigraphy must be performed in patients with neuroblastoma at the time of staging. The aim of this study is to identify the role of 131I-MIBG scintigraphy in neuroblastoma patients in correlation with other diagnostic modalities for staging of the disease. METHODS Twenty six patients provisionally diagnosed...
متن کاملAn intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
UNLABELLED The aim of this study was to compare the imaging abilities of the recently developed somatostatin analog, (99m)Tc-hydrazinonicotinyl-Tyr(3)-octreotide ((99m)Tc-HYNIC-TOC [(99m)Tc-TOC]), with (111)In-diethylenediaminepentaacetic acid-D-Phe(1)-octreotide ((111)In-OCT [Octreoscan]) in patients undergoing routine somatostatin receptor (SSTR) scintigraphy. METHODS Forty-one patients (20...
متن کاملSomatostatin receptor imaging in patients with neuroendocrine tumors: not only SPECT?
In this issue of The Journal of Nuclear Medicine, Gabriel et al. (1) report their experience with 68Ga-labeled 1,4,7,10tetraazacyclododecane-N,N9,N99,N999tetraacetic acid-D-Phe1-Tyr3-octreotide (68Ga-DOTA-TOC) PET in a series of 84 patients with neuroendocrine tumors (NET). PET was more accurate with a higher detection rate than somatostatin receptor scintigraphy (using 111In-DOTA-TOC or 99mTc-...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ذخیره در منابع من قبلا به منابع من ذحیره شده{@ msg_add @}
عنوان ژورنال
دوره 26 شماره 2
صفحات 68- 75
تاریخ انتشار 2018-07-01
با دنبال کردن یک ژورنال هنگامی که شماره جدید این ژورنال منتشر می شود به شما از طریق ایمیل اطلاع داده می شود.
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023